GlassScriptPhysician profile
Miranda B Binion
NPI 1093041139
$1,511.25
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $227 · 2021: $22.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $326.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $205.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $189.60 | 2019-2020 | |
| Novo Nordisk INC | $136.68 | 2019 | |
| Lilly USA, LLC | $132.91 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $64.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $54.75 | 2019-2020 | |
| Astellas Pharma US INC | $49.02 | 2019 | |
| Allergan, INC. | $42.51 | 2019-2020 | |
| Amarin Pharma, INC. | $42.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.65 | 2019 | |
| Daiichi Sankyo INC. | $34.86 | 2019 | |
| Pfizer INC. | $34.55 | 2020 | |
| Genentech USA, INC. | $32.99 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $28.91 | 2019 | |
| Abbvie INC. | $22.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.57 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.35 | 2020 | |
| Amgen INC. | $11.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Binion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.